Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions

Cited by (502)

Items 301–400 of 502

1. Uncontrolled Cardiovascular Risk Factors in Prostate Cancer Patients
   Shalini Moningi, Paul Linh Nguyen · 2023 · JACC CardioOncology
2. Neoadjuvant Hormonal Therapy Preceding Radical Prostatectomy for Clinically Localized Prostate Cancer: Early Postoperative Complications and Biochemical Recurrence
   Seung Woo Yang, Ki Hak Song, Jae Sung Lim, Chong-Koo Sul · 2011 · Korean journal of urology
3. Long-term Castration-related Outcomes in Patients With High-risk Localized Prostate Cancer Treated With Androgen Deprivation Therapy With or Without Docetaxel and Estramustine in the UNICANCER GETUG-12 Trial
   Clément Dumont, Giulia Baciarello, P. Bosset, Pernelle Lavaud, Émeline Colomba, Christophe Massard, Yohann Loriot, Laurence K. Albiges, Pierre Blanchard, Alberto Bossi et al. · 2020 · Clinical Genitourinary Cancer
4. Impact of Radiation on Cardiovascular Outcomes in Older Resectable Esophageal Cancer Patients With Medicare
   Reith Roy Sarkar, Ahmadreza Hatamipour, Neil Panjwani, P.T. Courtney, Daniel R. Cherry, Mia A. Salans, Anthony T. Yip, Brent Shane Rose, Daniel Robert Simpson, Matthew P. Banegas et al. · 2021 · American Journal of Clinical Oncology
5. Relugolix, An Oral Gonadotropin-Releasing Hormone Antagonist for the Treatment of Prostate Cancer
   Daniel J. George, David Paul Dearnaley · 2021 · Future Oncology
6. Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer
   Vinayak Muralidhar, Brandon Arvin Virgil Mahal, Brent Shane Rose, Yu‐Wei Chen, Michelle Daniel Nezolosky, Jason Alexander Efstathiou, Clair J. Beard, Neil E. Martin, Peter F. Orio, Quoc‐Dien Trinh et al. · 2016 · Clinical Genitourinary Cancer
7. Factors impacting all-cause mortality in prostate cancer brachytherapy patients with or without androgen deprivation therapy
   Al V. Taira, Gregory Stephen Merrick, Robert W. Galbreath, Wayne M. Butler, Kent E. Wallner · 2009 · Brachytherapy
8. Testosterone in men's health: a new role for an old hormone
   Robert J. Feeley, Farid Saad, André T. Guay, Abdulmaged M. Traish · 2009 · Journal of Men s Health
9. Clinical Practice Guidelines in Oncology TM
   Paul F. Engstrom, J. Pablo Arnoletti, Al B. Benson, Yi‐Jen Chen, Michael A. Choti, Harry S. Cooper, Anne M. Covey, Raza A. Dilawari, Dayna S. Early, Peter C. Enzinger et al. · 2009
10. Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy
    Atsushi Tomioka, Nobumichi Tanaka, Motokiyo Yoshikawa, Makito Miyake, Satoshi Anai, Yoshitomo Chihara, Eijiro Okajima, Akihide Hirayama, Yoshihiko Hirao, Kiyohide Fujimoto · 2015 · BMC Cancer
11. Androgen Deprivation Therapy Toxicity and Management for Men Receiving Radiation Therapy
    Matthew E. Johnson, Mark K. Buyyounouski · 2012 · Prostate Cancer
12. The side effects of hormonal therapy at the patients with prostate cancer
    L. Rydygier · 2012
13. Dosimetric analysis of testicular doses in prostate intensity-modulated and volumetric-modulated arc radiation therapy at different energy levels
    Cem Önal, Güngör Arslan, Yemliha Dölek, Esma Efe · 2016 · Medical dosimetry
14. The impact of comorbidity and PSA doubling time on the risk of death in men experiencing PSA failure following radiation therapy with or with androgen deprivation therapy for unfavorable-risk prostate cancer
    Sagar Anil Patel, M-H. Chen, Marian J. Loffredo, Andrew A. Renshaw, Philip W. Kantoff, A.V. D’Amico · 2017 · Prostate Cancer and Prostatic Diseases
15. Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease
    Alyssa K. Greiman, Thomas E. Keane · 2017 · Current Urology Reports
16. Cancer Therapies and Vascular Toxicities
    Alexandra Meilhac, Jennifer Cautela, Franck Thuny · 2022 · Current Treatment Options in Oncology
17. How can we best manage biochemical failure after radical prostatectomy?
    Won Tae Kim, Jiyeon Kim, Wun‐Jae Kim · 2022 · Korean journal of urology
18. Identification of comorbidities that place men at highest risk of death from androgen deprivation therapy before brachytherapy for prostate cancer
    A. Parekh, Ming‐Hui Chen, Anthony Victor D'Amico, Daniel E. Dosoretz, Rudi Ross, Sharon A. Salenius, Powell L. Graham, Joshua A. Beckman, Clair J. Beard, Toni K. Choueiri et al. · 2013 · Brachytherapy
19. Can prophylactic breast irradiation contribute to cardiac toxicity in patients with prostate cancer receiving androgen suppressing drugs?
    Carsten Nieder, Adam Pawinski, Nicolaus H. Andratschke, M. Molls · 2008 · Radiation Oncology
20. Defining the optimal approach to the patient with postradiation prostate‐specific antigen recurrence using outcome data from a prospective randomized trial
    Miranda B. Kim, Ming‐Hui Chen, Mário de Castro, Marian J. Loffredo, Philip W. Kantoff, Anthony Victor D'Amico · 2013 · Cancer
21. Androgen Deprivation Therapy for Prostate Cancer
    Stanislav Žiaran · 2011 · InTech eBooks
22. Evidence-based consensus recommendations to improve the quality of life in prostate cancer treatment
    Francesc Casas, Josep Maria Borràs, Ferran Ferrer, Núria Guanyabens, Rafael Gutiérrez del Pozo, Concha León, Jose López Torrecilla, Begoña Mellado, Juan Moróte, Manel Puig et al. · 2010 · Clinical & Translational Oncology
23. Cardiovascular Mortality and Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG/RTOG 9202
    Kimberley S. Mak, Molly Scannell Bryan, James J. Dignam, William U. Shipley, Yue Lin, Christopher A. Peters, Elizabeth Gore, Seth A. Rosenthal, Kenneth Lee Zeitzer, David Paul D'Souza et al. · 2024 · European Urology Focus
24. Weighing Risk of Cardiovascular Mortality Against Potential Benefit of Hormonal Therapy in Intermediate-Risk Prostate Cancer
    Nataniel Hernan Lester-Coll, Skyler Bryce Johnson, William J. Magnuson, Samuel Zachary Goldhaber, David Jonathan Sher, Anthony Victor D'Amico, James B. Yu · 2016 · JNCI Journal of the National Cancer Institute
25. Conventional androgen deprivation therapy is associated with an increased risk of cardiovascular disease in advanced prostate cancer, a nationwide population-based study
    Jian‐Ri Li, Shian‐Shiang Wang, Chuan-Shu Chen, Chen‐Li Cheng, Sheng-Chun Hung, Ching‐Heng Lin, Kun‐Yuan Chiu · 2022 · PLoS ONE
26. Impact of the duration of hormonal therapy following radiotherapy for localized prostate cancer
    Mitsuru Okubo, Hidetsugu Nakayama, Tomohiro Itonaga, Yu Tajima, Sachika Shiraishi, Ryuji Mikami, Akira Sakurada, Shinji Sugahara, Kiyoshi Koizumi, Koichi Tokuuye · 2015 · Oncology Letters
27. Traditional Approaches to Androgen Deprivation Therapy
    Judd W. Moul, Christopher P. Evans, Leonard G. Gomella, Mack Roach, Robert Dreicer · 2011 · Urology
28. Patterns of failure after iodine-125 seed implantation for prostate cancer
    David S. Lamb, Lynne Greig, Grant L. Russell, John N. Nacey, Kim E. Broome, Rod Studd, Brett Delahunt, Douglas Iupati, Mohua Jain, Colin Rooney et al. · 2014 · Radiotherapy and Oncology
29. Evaluation of primary androgen deprivation therapy in prostate cancer patients using the J-CAPRA risk score
    Hideyuki Akaza, Shiro Hinotsu, Michiyuki Usami, Osamu Ogawa, Tadaichi Kitamura, Kazuhiro Suzuki, Taiji Tsukamoto, Seiji Naito, Mikio Namiki, Yoshihiko Hirao et al. · 2013 · Prostate International
30. Does Prophylactic Breast Irradiation in Patients With Prostate Cancer Influence Cardiac Toxicity?
    Carsten Nieder, Adam Pawinski, Nicolaus H. Andratschke, M. Molls · 2007 · JNCI Journal of the National Cancer Institute
31. The Use of Gonadotropin-Releasing Hormone Agonist Does Not Affect the Development of Cardiovascular Disease in Prostate Cancer Patients: a Nationwide Population-Based Cohort Study
    Myungsun Shim, Woo Jin Bang, Cheol Young Oh, Yong‐Seong Lee, Seong Soo Jeon, Hanjong Ahn, Young‐Su Ju, Jin Seon Cho · 2020 · Journal of Korean Medical Science
32. Cardiovascular mortality and androgen deprivation
    Shehzad Sultan Basaria · 2009 · Nature Reviews Urology
33. The impact of age on clinicopathological features and treatment results in patients with localised prostate cancer receiving definitive radiotherapy
    Cem Önal, Ozan Cem Güler, Ayşenur Elmalı, Birhan Demirhan, Melek Yavuz · 2024 · Acta Oncologica
34. Primary androgen deprivation therapy as monotherapy in unfavourable intermediate- and high-risk localised prostate cancer: a Singaporean single-centre perspective
    Han Jie Lee, Alvin Yuan Ming Lee, Hong Hong Huang, Weber Kam On Lau · 2018 · International Urology and Nephrology
35. Effects and moderators of exercise medicine on cardiometabolic outcomes in men with prostate cancer previously or currently undergoing androgen deprivation therapy: An individual patient data meta-analysis
    Pedro López, Robert Usher Newton, Dennis R. Taaffe, Kerri M. Winters‐Stone, Laurien M. Buffart, Daniel Abido Galvao · 2023 · Critical Reviews in Oncology/Hematology
36. Hormone use after radiotherapy failure: a survey of Canadian uro-oncology specialists
    D. Andrew Loblaw, Tom Pickles, Patrick Cheung, Himu R. Lukka, Sérgio Luis Faria, Laurence H. Klotz · 2013 · Canadian Urological Association Journal
37. Complications de l’hormonothérapie anti-androgénique du cancer de la prostate
    Imad Ziouziou, Tariq Karmouni, Khalid El Khader, Abdellatif Koutani, Aahmed Iben attya andaloussi · 2014 · Canadian Urological Association Journal
38. Combination of androgen deprivation therapy and radiotherapy for localized prostate cancer in the contemporary era
    Rolando Maria D’Angelillo, Pierfrancesco Franco, Berardino De Bari, Alba Fiorentino, Stefano Arcangeli, Filippo Alongi · 2014 · Critical Reviews in Oncology/Hematology
39. Observation for Clinically Localized Prostate Cancer
    Joel B. Nelson · 2014 · Journal of Clinical Oncology
40. The clinical significance of biochemical failure in the first 2 years in patients treated with neo-adjuvant androgen deprivation and radiotherapy for prostate cancer
    Fergal C. Kelleher, Dunne MT, Collins IM, Finn MA, C. O'Shea, Armstrong Jg · 2013 · Research Journal of Infectious Diseases
41. Protocol for a phase III RCT and economic analysis of two exercise delivery methods in men with PC on ADT
    Shabbir M.H. Alibhai, Paul Ritvo, Daniel Santa Mina, Catherine Michelle Sabiston, Murray Dale Krahn, GEORGE A. TOMLINSON, Andrew Matthew, Himu R. Lukka, Padraig Richard Warde, Sara Durbano et al. · 2018 · BMC Cancer
42. Syndrome métabolique et insulinorésistance chez les patients atteints de cancer de la prostate traités par suppression androgénique hormonale
    J.-E. Terrier, Nicolas Mottet · 2012 · The French Journal of Urology
43. Outcomes of patients older than 75 years with non-metastatic prostate cancer
    Yoshiyasu Amiya, Yasutaka Yamada, Masahiro Sugiura, Makoto Sasaki, Takayuki Shima, Noriyuki Suzuki, Hiroomi Nakatsu, Shino Murakami, Jun Shimazaki · 2017 · Asian journal of urology
44. Practically scheduling hormone therapy for prostate cancer using a mathematical model
    Ayako Nakanishi, Yoshito Hirata · 2019 · Journal of Theoretical Biology
45. Clinical Outcomes of Dose-escalated Radiotherapy for Localised Prostate Cancer: A Single-institution Experience
    Katherine Meng, Keith Hsiu Chin Lim, Chia Ching Lee, David Chia, Kiat Huat Ooi, Yu Yang Soon, Jeremy Chee Seong Tey · 2020 · In Vivo
46. External radiotherapy for prostate cancer with or without androgen deprivation: Geneva, 1991 to 2004
    Raymond Miralbell, S. Pampallona, M Rouzaud, Angela Pugliesi, D Weber, Carmen Ares · 2009 · Swiss Medical Weekly
47. Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
    Claude C. Schulman · 2009 · European Urology Supplements
48. A practical guide for assessing and managing cardiovascular risk during androgen‐deprivation therapy in patients with prostate cancer
    Aum Solanki, Mitchell R. Kamrava, Edwin M. Posadas, Stephen J. Freedland, Leslie Ballas, Howard Mark Sandler, C. Noel Bairey Merz, Katelyn M. Atkins, Andriana Nikolova · 2024 · Cancer
49. Real‐world insights into risk of developing cardiovascular disease following Gn RH agonists versus antagonists for prostate cancer: a methodological protocol to a study using five European databases
    Gincy George, Lucie‐Marie Scailteux, Hans Garmo, Frédéric Balusson, Chris R. Cardwell, Greet De Coster, Harlinde De Schutter, Josephina G. Kuiper, Úna C. McMenamin, Julie Verbeeck et al. · 2019 · Fundamental and Clinical Pharmacology
50. Renal Impairment: A Major Adverse Event in Prostate Cancer Patients Treated With Androgen Deprivation Therapy
    Hiroshi Masuda · 2022 · Anticancer Research
51. Cardiovascular risks in men with prostate cancer: a pragmatic, clinician-oriented review of risk stratification and management strategies
    Aditya H. Bhave, Harikrishnan Hyma Kunhiraman, Tarek Nahle, Ritu Reddy, Omar Mohamed Makram, Priyanshu Nain, Viraj R Shah, Umang Swami, Sagar Anil Patel, Ashanda Rosetta Patrice Esdaille et al. · 2025 · Prostate Cancer and Prostatic Diseases
52. Impacto de la supresión androgénica sobre el perfil lipídico y el riesgo aterogénico en pacientes con cáncer de próstata
    Carlos Salvador, Jacques Planas, Carles Xavier Raventos, J. Ropero, José Placer, M.A. López, Juan Moróte · 2012 · Actas Urológicas Españolas
53. Hormonothérapie combinée à la radiothérapie externe dans le cancer de prostate localement avancé : les effets secondaires contrecarrent-ils les bénéfices ?
    Sarah Drouin, Morgan Rouprêt A, Alberto Bossi, M. Bolla · 2010 · The French Journal of Urology
54. Clinical efficacy of primary combined androgen blockade for Japanese men with clinically localized prostate cancer unsuitable for local definitive treatment: a single institution experience
    Minoru Kobayashi, Akinori Nukui, Kazumi Suzuki, Shinsuke Kurokawa, Tatsuo Morita · 2011 · International Journal of Clinical Oncology
55. The role of androgen deprivation therapy plus radiation therapy in patients with non-metastatic prostate cancer
    Sherry S. Zhao, Alfredo I. Urdaneta, Mitchell Steven Anscher · 2016 · Expert Review of Anticancer Therapy
56. Indications and Practice With Androgen Deprivation Therapy
    Judd W. Moul, Adam Stuart Kibel, Mack Roach, Robert Dreicer · 2011 · Urology
57. Impact of Androgen Deprivation Therapy on Overall Mortality in Prostate Brachytherapy Patients With Low Pretreatment Testosterone Levels
    Al V. Taira, Gregory Stephen Merrick, Robert W. Galbreath, Wayne M. Butler, Edward Adamovich · 2016 · American Journal of Clinical Oncology
58. Androgens and Coronary Artery Disease
    Fredrick C. W. Wu, Arnold von Eckardstein · 2003 · Humana Press eBooks
59. Androgen deprivation therapy and cardiovascular complications
    Z. Poljak, I Hulín, L. Maruscakova, A. Carter, Beáta Mladosievičová · 2017 · Bratislavské lekárske listy/Bratislava medical journal
60. Treatment of Localized Prostate Cancer
    Andrew J. Stephenson · 2012 · Humana Press eBooks
61. New antidiabetic drugs' role in the management of testosterone deficiency and of the cardiovascular disease in hypogonadal diabetic men
    Valentina Annamaria Genchi, Eleonora Zanni, Massimiliano Colzani, Celeste Lauriola, Angelo Cignarelli, Daniele Santi, Carla Greco · 2023 · Metabolism and Target Organ Damage
62. Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Phase 3 Trials
    Krishnan R. Patel, Paul L. Nguyen, James A. Proudfoot, Yang Liu, Alan Dal Pra, Daniel Eidelberg Spratt, Alan S Pollack, Howard Mark Sandler, Jason Alexander Efstathiou, C.A. Lawton et al. · 2024 · European Urology Oncology
63. Impact of androgen deprivation on the lipid profile and atherogenic risk in prostate cancer patients
    Carlos Salvador, Jacques Planas, Carles Xavier Raventos, J. Ropero, José Placer, M.A. López, Juan Moróte · 2012 · Actas Urológicas Españolas (English Edition)
64. Association de radiothérapie et d’hormonothérapie dans la prise en charge des cancers localisés de la prostate : où en est-on ?
    S. Bellefqih, Khalid Hadadi, Imane Mezouri, Abdelhak Maghous, Elamin Marnouche, Khalid Andaloussi, Mohamed Elmarjany, Hassan Sifat, Hamid Mansouri, Noureddine Benjaafar · 2016 · Cancer/Radiothérapie
65. Definitive Therapy for Localized Prostate Cancer
    William J. Catàlona, Misop Han · 2012 · Elsevier eBooks
66. Thrombo-inflammation linking androgen suppression with cardiovascular risk in patients with prostate cancer
    Antonia Beitzen‐Heineke, David R. Wise, Jeffrey S. Berger · 2024 · Cardio-Oncology
67. Androgen Deprivation Therapy for Prostate Cancer: Effects on Body Composition and Metabolic Health
    Grace Tzu-Wei Huang, Shehzad Sultan Basaria · 2017 · Energy balance and cancer
68. 125I Interstitial brachytherapy with or without androgen deprivation therapy among unfavorable-intermediate and high-risk prostate cancer
    Timothy D. Smile, Martin C. Tom, Ahmed Halima, Jay P. Ciezki, Chandana A. Reddy, Kevin L. Stephans, Omar Y. Mian, Ryan X. Zhang, Eric A. Klein, Steven C. Campbell et al. · 2021 · Brachytherapy
69. Management of Biochemical Recurrence of Prostate Cancer After Curative Treatment: A Focus on Older Patients
    Lancelot Tremeau, Nicolas Mottet · 2022 · Drugs & Aging
70. Riscos cardiovasculares do bloqueio androgênico
    Adriano Freitas Ribeiro, César Câmara, Carlos Alexandre Wainrober Segre, Miguel Srougi, Carlos Vicente Serrano Junior · 2010 · Arquivos Brasileiros de Cardiologia
71. Caring for Alaska Native prostate cancer survivors in primary care: a survey of Alaska Tribal Health System providers
    Jon Charles Tilburt, Stacy F. Kelley, Christine A. Decourtney, Katherine M. Humeniuk, Jerilyn M. Latini, Simon P. Kim · 2014 · International Journal of Circumpolar Health
72. Short term effects of GnRH agonists on plasma fibrinolytic balance in patients with advanced prostate cancer
    Mehmet Ali Ağırbaşlı, Oytun A. Baykan, Ali Tekin, Feridun Şengör, Altug A. Cincin, Muzaffer Demir, Douglas E. Vaughan · 2008 · Journal of Thrombosis and Thrombolysis
73. Does short-term ADT before and during radiation therapy improve outcomes in locally advanced prostate cancer?
    Emmanuel S. Antonarakis, Mario A. Eisenberger · 2008 · Nature Clinical Practice Urology
74. Testosterone deficiency syndrome and cardiovascular health: An assessment of beliefs, knowledge and practice of general practitioners and cardiologists in Victoria, BC
    Christopher J. D. Wallis, Hilary L. Nelson, Peter J. Pommerville · 2014 · Canadian Urological Association Journal
75. Testosterone Replacement Therapy and the Cardiovascular System
    Sahar Naderi · 2016 · Current Atherosclerosis Reports
76. Cancer de prostate des sujets âgés : place et rôle de l’évaluation gériatrique
    Benoîte Méry, Alexis Vallard, Sophie Espenel, Nicole Badie, Magali Thiermant, V. Lambert, Victor Soulier, Sylvain Piqueres, K. Del Santo, Majed Ben Mrad et al. · 2016 · The French Journal of Urology
77. Prostate Cancer
    Jeff M. Michalski, Thomas Michael Pisansky, C.A. Lawton, Louis Potters · 2015 · Elsevier eBooks
78. Oncoforum en Urologie et Revue de la littérature
    Christophe Hennequin · 2008 · Cancer/Radiothérapie
79. Does the Benefit Justify the Risk?
    Peter C. Albertsen · 2009 · JNCI Journal of the National Cancer Institute
80. Look and You Will Find It: Practical Considerations for Improving Multidisciplinary Management of Androgen-Deprivation Therapy–Induced Cardiometabolic Toxicity
    Michel Georges Khouri, Michael Roger Harrison · 2018 · Journal of Oncology Practice
81. Modifiable Cardiovascular Risk Factors Amongst Men With and Without Prostate Cancer in a Large, Prospective Registry
    James Robert Janopaul-Naylor, ADITHYA K. YADALAM, Jeffrey Shi Kai Chan, Edward Christopher Dee, Yan V. Sun, Stephanie M. Cantú, Anant Mandawat, Sagar Anil Patel · 2025 · Clinical Genitourinary Cancer
82. Evidence‐based medicine: comparative analysis of luteinizing hormone‐releasing hormone analogues in combination with external beam radiation and surgery in the treatment of carcinoma of the prostate
    Santiago Vilar González, Xavier Maldonado · 2010 · British Journal of Urology
83. Cardiovascular toxicities of therapy for genitourinary malignancies
    Vivek Narayan, David J. Vaughn, Bonnie Ky · 2019 · Urologic Oncology Seminars and Original Investigations
84. Prostate cancer radiotherapy and incidental testicular irradiation: Impact on gonadal function
    Jennifer Le Guévelou, Thomas Zilli · 2023 · Clinical and Translational Radiation Oncology
85. Interaction of adjuvant androgen deprivation therapy with patient comorbidity status on overall survival after radical prostatectomy for high‐risk prostate cancer
    Brian J. Linder, Stephen Anthony Boorjian, Eric C. Umbreit, Rachel E. Carlson, Laureano J. Rangel, Eric J. Bergstralh, Robert Jeffrey Karnes · 2012 · International Journal of Urology
86. CARDIOVASCULAR RISK ASSOCIATED WITH ANDROGEN DEPRIVATION THERAPY IN ADVANCED PROSTATE CANCER
    DEEPTHI C DENNY, YOGAVADULA SS, R VIJAY, Mohamed Fardan, DIVYA SARA IYPE, ABI MAHESHWARAN K · 2021 · Asian Journal of Pharmaceutical and Clinical Research
87. Role of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate cancer.
    Abhishek A Solanki, Stanley L. Liauw · 2011 · Europe PMC (PubMed Central)
88. Primary androgen deprivation (AD) followed by active surveillance (AS) for newly diagnosed prostate cancer (PC): A retrospective study
    Mark Creamer Scholz, Meg Groom, Andrew Kaddis, Stephen Bruce Strum, Robert I. Jennrich, Duke K. Bahn, Patricia J. Chang, Lauren K. Becker, Richard Y. Lam · 2012 · The Prostate
89. ADT for prostate cancer: true love or heartbreak?
    Jason Alexander Efstathiou, William U. Shipley, Anthony Laurence Zietman, Matthew R. Smith · 2010 · Nature Reviews Clinical Oncology
90. Monitoring cardiovascular health in men with prostate cancer treated with androgen deprivation therapy
    Carolyn A Allan, Veronica Collins, Mark Frydenberg, Robert Ian McLachlan, Kati L. Matthiesson · 2012 · International Journal of Urological Nursing
91. Prevalence of Diabetes Mellitus and Metabolic Syndrome in Prostate Cancer Patients given Androgen Deprivation Therapy
    M. L. C. Rivera-Arkoncel, Michael Sagun, Francis Raymond P. Arkoncel, Cecilia Jimeno, Marie Carmela Lapitan · 2014 · Journal of the ASEAN Federation of Endocrine Societies
92. Radiation Therapy for Prostate Cancer
    Bridget F. Koontz, William Robert Lee · 2013 · Surgical Oncology Clinics of North America
93. Cancer of the Prostate
    Mack Roach, Kent E. Wallner, I-Chow Joe Hsu, Peter R. Carroll · 2010 · Elsevier eBooks
94. Treatment Options in Oligometastatic Disease in Prostate Cancer: Thinking Outside the Box
    Christopher W. Fleming, James R. Broughman, Rahul D. Tendulkar · 2020 · Current Treatment Options in Oncology
95. Short-term ADT and Dose-escalated IMRT in Patients With Intermediate-risk Prostate Cancer
    Carl M. Post, Jenna M. Kahn, Claire B. Turina, Tomasz M. Beer, Arthur Y. Hung · 2022 · American Journal of Clinical Oncology
96. Androgen deficiency in the male
    Gregory Clyde Mitchell, Wayne J.G. Hellstrom · 2013 · Cambridge University Press eBooks
97. Étude observationnelle CAPITAL et prescription de l’hormonotherapie par les urologues français dans la pratique quotidienne
    Alexandre DE LA TAILLE, Sarah Drouin, Morgan Rouprêt A, P. Perrin, Marc Zerbib · 2009 · The French Journal of Urology
98. Competing Risks for Patients With Localized Prostate Cancer
    Jerome Seidenfeld, D. Samson, Peter C. Albertsen · 2007 · JNCI Journal of the National Cancer Institute
99. Locally Advanced Prostate Cancer Biochemical Recurrence after Radiotherapy: Use of Cyclic Androgen Withdrawal Therapy
    Juanita Mary Crook · 2008 · Springer eBooks
100. Is androgen suppression therapy associated with early onset of fatal myocardial infarction?
     Martin George Sanda, Mohit S. Kasibhatla · 2008 · Nature Clinical Practice Urology